Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis
Copyright © 2023 by the Journal of Rheumatology..
OBJECTIVE: Previous studies suggested that distinct phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) could be determined by the presence or absence of antineutrophil cytoplasmic antibodies (ANCA), reflecting predominant vasculitic or eosinophilic processes, respectively. This study explored whether ANCA-based clusters or other clusters can be identified in EGPA.
METHODS: This study used standardized data of 15 European centers for patients with EGPA fulfilling widely accepted classification criteria. We used multiple correspondence analysis, hierarchical cluster analysis, and a decision tree model. The main model included 10 clinical variables (musculoskeletal [MSK], mucocutaneous, ophthalmological, ENT, cardiovascular, pulmonary, gastrointestinal, renal, central, or peripheral neurological involvement); a second model also included ANCA results.
RESULTS: The analyses included 489 patients diagnosed between 1984 and 2015. ANCA were detected in 37.2% of patients, mostly perinuclear ANCA (85.4%) and/or antimyeloperoxidase (87%). Compared with ANCA-negative patients, those with ANCA had more renal (P < 0.001) and peripheral neurological involvement (P = 0.04), fewer cardiovascular signs (P < 0.001), and fewer biopsies with eosinophilic tissue infiltrates (P = 0.001). The cluster analyses generated 4 (model without ANCA) and 5 clusters (model with ANCA). Both models identified 3 identical clusters of 34, 39, and 40 patients according to the presence or absence of ENT, central nervous system, and ophthalmological involvement. Peripheral neurological and cardiovascular involvement were not predictive characteristics.
CONCLUSION: Although reinforcing the known association of ANCA status with clinical manifestations, cluster analysis does not support a complete separation of EGPA in ANCA-positive and -negative subsets. Collectively, these data indicate that EGPA should be regarded as a phenotypic spectrum rather than a dichotomous disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
The Journal of rheumatology - 50(2023), 11 vom: 05. Nov., Seite 1446-1453 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rubenstein, Emma [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Antineutrophil Cytoplasmic |
|---|
| Anmerkungen: |
Date Completed 03.11.2023 Date Revised 16.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3899/jrheum.2023-0325 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362359857 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362359857 | ||
| 003 | DE-627 | ||
| 005 | 20240117231948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3899/jrheum.2023-0325 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1262.xml |
| 035 | |a (DE-627)NLM362359857 | ||
| 035 | |a (NLM)37739478 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rubenstein, Emma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.11.2023 | ||
| 500 | |a Date Revised 16.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by the Journal of Rheumatology. | ||
| 520 | |a OBJECTIVE: Previous studies suggested that distinct phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) could be determined by the presence or absence of antineutrophil cytoplasmic antibodies (ANCA), reflecting predominant vasculitic or eosinophilic processes, respectively. This study explored whether ANCA-based clusters or other clusters can be identified in EGPA | ||
| 520 | |a METHODS: This study used standardized data of 15 European centers for patients with EGPA fulfilling widely accepted classification criteria. We used multiple correspondence analysis, hierarchical cluster analysis, and a decision tree model. The main model included 10 clinical variables (musculoskeletal [MSK], mucocutaneous, ophthalmological, ENT, cardiovascular, pulmonary, gastrointestinal, renal, central, or peripheral neurological involvement); a second model also included ANCA results | ||
| 520 | |a RESULTS: The analyses included 489 patients diagnosed between 1984 and 2015. ANCA were detected in 37.2% of patients, mostly perinuclear ANCA (85.4%) and/or antimyeloperoxidase (87%). Compared with ANCA-negative patients, those with ANCA had more renal (P < 0.001) and peripheral neurological involvement (P = 0.04), fewer cardiovascular signs (P < 0.001), and fewer biopsies with eosinophilic tissue infiltrates (P = 0.001). The cluster analyses generated 4 (model without ANCA) and 5 clusters (model with ANCA). Both models identified 3 identical clusters of 34, 39, and 40 patients according to the presence or absence of ENT, central nervous system, and ophthalmological involvement. Peripheral neurological and cardiovascular involvement were not predictive characteristics | ||
| 520 | |a CONCLUSION: Although reinforcing the known association of ANCA status with clinical manifestations, cluster analysis does not support a complete separation of EGPA in ANCA-positive and -negative subsets. Collectively, these data indicate that EGPA should be regarded as a phenotypic spectrum rather than a dichotomous disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antineutrophil cytoplasmic antibody–associated vasculitis | |
| 650 | 4 | |a eosinophilic granulomatous vasculitis | |
| 650 | 4 | |a vasculitis | |
| 650 | 7 | |a Antibodies, Antineutrophil Cytoplasmic |2 NLM | |
| 700 | 1 | |a Maldini, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Vaglio, Augusto |e verfasserin |4 aut | |
| 700 | 1 | |a Bello, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Bremer, Jan Phillip |e verfasserin |4 aut | |
| 700 | 1 | |a Moosig, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Bottero, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Pesci, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Sinico, Renato Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Grosskreutz, Julian |e verfasserin |4 aut | |
| 700 | 1 | |a Feder, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Saadoun, David |e verfasserin |4 aut | |
| 700 | 1 | |a Trivioli, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Maritati, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Rewerska, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Szczeklik, Wojciech |e verfasserin |4 aut | |
| 700 | 1 | |a Fraticelli, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Guida, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Gregorini, Gina |e verfasserin |4 aut | |
| 700 | 1 | |a Moroncini, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Hellmich, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a Zwerina, Jochen |e verfasserin |4 aut | |
| 700 | 1 | |a Resche-Rigon, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Emmi, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Neumann, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Mahr, Alfred |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of rheumatology |d 1983 |g 50(2023), 11 vom: 05. Nov., Seite 1446-1453 |w (DE-627)NLM000019593 |x 1499-2752 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:11 |g day:05 |g month:11 |g pages:1446-1453 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3899/jrheum.2023-0325 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 11 |b 05 |c 11 |h 1446-1453 | ||